MedTrace Logo

Volasertib in Japanese Patients With Acute Myeloid Leukemia (AML)

NCT01662505 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2018-07-30

Study results available
· View outcomes & findings →

Summary

To investigate safety, tolerability, maximum tolerated dose of volasertib in Japanese patients with AML

Conditions

  • Leukemia, Myeloid, Acute

Interventions

DRUG

Volasertib

Patient to receive volasertib

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2015-05-31
Completion
2015-05-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01662505 on ClinicalTrials.gov